AGN:CC - Algernon Pharmaceuticals: Clinical Stage Drug Development Company

Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon is in the early planning stages of its clinical research program and is considering the option of conducting its initial trial in Australia.

The Company is also planning to conduct trials in the U.S. and will accordingly file a pre-IND application with the U.S. Food and Drug Administration.

Additionally, the Company is planning to conduct a small Phase 1 study in Q4, 2022, to determine the bioavailability of its newly planned Repirinast finished product.

For more information on Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) please click the request investor info button.

The post Algernon Pharmaceuticals: Clinical Stage Drug Development Company appeared first on BTV News .